OSUR Company Profile

In the most recent fiscal period company decreased a loss per share at $-0.98 per share, opposite of $-1.06 per share a year before financial reporting period, In the preceding financial reporting period Impel Pharmaceuticals Inc realized $-1.31 per share.

Focusing on the financial interval ending December 31 2022 CTMX lost money at $-0.42 per share, relative to the results of $-0.91 per share a year before quarter, In the previous quarter CTMX realized $-0.35 per share.

For the fiscal time-frame closing December 31 2022 Acer Therapeutics Inc increased a loss per share of $-0.54 per share compare to $-0.30 a year prior and grew loss from $-0.31 per share from the preceding reporting period.

Sales remained unaltered to $0.00 millions from $0.36 millions in the same reporting period a year prior and sequentially Sales Tumbled from $0.00 millions.

A humbling fiscal period by the company amid the fourth quarter of 2022

For the fourth quarter of 2022 earnings season company Deficit has extended of $-7.81 per share compare to $-0.43 a year before and EPS improved from $-14.52 per share from the preceding quarter.

Sales depreciated by -5.307 % to $80.65 millions from $85.17 millions in the comparable quarter a year before and sequentially Sales advanced by 10.767 % from $72.81 millions.

For the financial period ending December 31 2022 company decreased a loss per share of $-0.23 per share compare to $-0.56 a year prior and EPS improved from $-0.44 per share from the preceding reporting period.

Sales remained unchanged to $0.00 millions from $1.00 millions in the corresponding reporting period a year prior and sequentially Sales advanced from $0.00 millions.